TN-501 is a precise in vivo gene editing therapy that inactivates the mutant PLN-R14delallele to correct the underlying genetic cause of PLN- R14del-associated cardiomyopathy, showing strong preclinical …

What is a positive PLN result? ic change (variant) was found in the PLN gene. A positive PLN variant is considered “pathogenic” or “likely pathogenic” because it increases the chance to develop …

Life-critical applications include devices identified by the U.S. Food and Drug Administration as Class III devices and generally equivalent classifications outside of the United States.

Resistant to common cleaning agents and lubricants and FDA-compliant. Configurable product This product and all its product options can be ordered online via the configurator. For standard O.D. …

In this study, by using CRISPR-Cas9 gene editing technology, we constructed the PLN-R14del mouse model and hESCs. The PLNR14del/R14delmice developed severe ventricular dilation, cardiac...

PLN-101095 is a novel, orally bioavailable small molecule that effectively inhibits integrins alpha-V-beta 8 (αvβ8) and alpha-V-beta 1 (αvβ1) by preventing binding to the latency-associated peptide of …

We previously tested our gene editing therapy in patient-specific human iPSC-derived cardiomyocytes (iPSC-CMs) and found that hTNGE101 precisely and efficiently edited the PLN-R14del allele without …